The ISSCR supports the increase in biomedical research funding in the 21st Century Cures Act in the U.S. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.

The ISSCR supports the increase in biomedical research funding in the current version of the 21st Century Cures Act. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.

In comments to the Australian Therapeutic Goods Administration (TGA), the ISSCR supported regulation of autologous products that involve more than minimal manipulation of a patient’s cells and place strict limitations on the direct advertisement of cell-based therapies. The comments were in response to the TGA's call for input from interested parties about the regulation of autologous cell and tissue products.

The European Society of Gene and Cell Therapy (ESGCT) & ISSCR host an International Symposium to Present the Latest in Stem Cell Research, Gene Editing and Gene Therapy. Latest news and developments in research will be part of the scientific programming.

The ISSCR opposes the REGROW Act, which would allow certain cell and tissue-based therapeutics to be marketed without first providing rigorous evidence of safety and efficacy. If passed, this legislation could negatively impact the development of stem cell therapies, the integrity of the emerging regenerative medicine market, and the health and safety of people using stem cell products approved under this Act.

The ISSCR today underscored the need for careful oversight and regulation of stem cell research at every stage in the process of developing therapeutic products for patient use.

The ISSCR supports the continued assessment of the U.S. National Institutes of Health (NIH) Guidelines for Human Stem Cell Research. We applaud the proposed end to the current moratorium on U.S. federal funding of human-animal chimera research involving the introduction of human pluripotent cells into early stage animal embryos.

The ISSCR is pleased that the U.S. National Institutes of Health (NIH) is considering an end to the moratorium on NIH funding of human-animal chimera research (NIH Notice, 8-4-16).

The ISSCR provided comments to the National Academy of Science/National Academy of Medicine Committee on Human Gene Editing regarding scientific, medical, and ethical considerations.

The ISSCR Announces Los Angeles, CA as the site of its 2019 annual meeting, noting that it's the first time the organization will be meeting in that city. ISSCR 2019 is expected to draw more than 3,000 stem cell researchers and professionals from around the globe to the Los Angeles Convention Center 26-29 June, 2019.

The ISSCR, the world’s largest professional organization of stem cell scientists, today released newly updated guidelines for stem cell research and the development of new clinical therapies. Guidance addresses key scientific, ethical, social, and policy challenges raised by new technologies and emerging areas of stem cell discovery and application.

The ISSCR announces an RFP for co-sponsorship of the 2021 annual meeting

The International Society for Stem Cell Research (ISSCR) is the world’s leading professional organization of stem cell scientists, representing more than 4,000 members in 45 U.S. states and 65 countries around the world. The ISSCR is opposed to recent efforts to inappropriately limit or prohibit biomedical research using fetal tissue. These proposals, if enacted, would obstruct critical biomedical research and inhibit efforts to improve human health. If enacted in the past, such limits would have delayed or prevented the development of therapies that have saved millions of lives.

The International Society for Stem Cell Research (ISSCR) is excited to announce the society’s 2016 award recipients, who will be formally recognized at its annual meeting, taking place 22-25 June, 2016 in San Francisco, California, U.S.